Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription


1 Am J Clin Pathol
13 Ann Surg Oncol
3 BMC Cancer
1 Br J Cancer
2 Breast Cancer (Dove Med Press)
3 Breast Cancer Res
6 Breast Cancer Res Treat
2 Cancer
2 Cancer Epidemiol Biomarkers Prev
1 Cancer Lett
1 Cancer Res
2 Clin Breast Cancer
1 Eur J Cancer
1 Eur J Surg Oncol
1 Histopathology
1 Int J Cancer
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
2 J Clin Oncol
3 J Natl Cancer Inst
3 J Surg Oncol
7 Mod Pathol
2 N Engl J Med
1 NPJ Breast Cancer
1 Oncol Rep
2 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. ZHANG M, Liao J, Jia Z, Qin C, et al
    High Dynamic Range Dual-Modal White Light Imaging Improves the Accuracy of Tumor Bed Sampling After Neoadjuvant Therapy for Breast Cancer.
    Am J Clin Pathol. 2023 Feb 17:aqac167. doi: 10.1093.
    PubMed         Abstract available

    Ann Surg Oncol

  2. CLARK NM, Roberts EA, Fedorenko C, Sun Q, et al
    Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Ann Surg Oncol. 2023;30:1312-1326.
    PubMed         Abstract available

  3. YAMAGUCHI A, Ishitobi M, Nagura N, Shimo A, et al
    Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.
    Ann Surg Oncol. 2023;30:1678-1686.
    PubMed         Abstract available

  4. ISHITOBI M, Shien T
    ASO Author Reflections: Is Nipple-Areolar Recurrence After Nipple-Sparing Mastectomy Simply a "Cosmetic Failure"?
    Ann Surg Oncol. 2023;30:1687-1688.

  5. CLARK NM, Roberts EA, Federenko C, Sun Q, et al
    ASO Visual Abstract: Genetic Testing Among Patients with High-Risk Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Ann Surg Oncol. 2023;30:1329-1330.

  6. CHETTRI SR, Pignone MP, Deal AM, Sepucha KR, et al
    Patient-Reported Outcomes of Breast Reconstruction: Does the Quality of Decisions Matter?
    Ann Surg Oncol. 2023;30:1891-1900.
    PubMed         Abstract available

  7. MOLDOVEANU D, Iny E, Theriault C, Florea A, et al
    Margin Status and Local Recurrence in Phyllodes Tumours of the Breast: A Canadian Series.
    Ann Surg Oncol. 2023;30:1700-1709.
    PubMed         Abstract available

  8. INY E, Prakash I
    ASO Author Reflections: Surgical Management of Phyllodes Tumors of the Breast.
    Ann Surg Oncol. 2023;30:1710-1711.

  9. GONZALEZ GARCIA JA, Rodriguez Alvarado EI, Gutierrez Ramirez MC, Laforga Canales JB, et al
    Magnetic-Guided Occult Lesion Localization (M-GOLL): An Exploratory Feasibility Study of Preoperative CT-Guided Puncture and Intraoperative Magnetic Seed Localization for Minimally Invasive Surgical Resection of Non-palpable Pulmonary Lesions.
    Ann Surg Oncol. 2023;30:1309-1311.

  10. ELLSWORTH BL, Settecerri DJ, Mott NM, Vastardis A, et al
    Surgeon Perspectives on Determinants of Same-Day Mastectomy: A Roadmap for Implementing Change.
    Ann Surg Oncol. 2023;30:1712-1720.
    PubMed         Abstract available

  11. CHETTRI SR, Pignone MP, Deal AM, Sepucha KR, et al
    ASO Visual Abstract: Patient-Reported Outcomes of Breast Reconstruction: Does the Quality of Decisions Matter?
    Ann Surg Oncol. 2023;30:1902-1903.

  12. CHETTRI SR, Lee CN
    ASO Author Reflections: Breast Reconstruction Decision Quality and Patient-Reported Outcomes.
    Ann Surg Oncol. 2023;30:1901.

  13. ELLSWORTH BL, Settecerri DJ, Mott NM, Vastardis A, et al
    ASO Visual Abstract: Surgeon Perspectives on Determinants of Same-Day Mastectomy: A Roadmap for Implementing Change.
    Ann Surg Oncol. 2023;30:1721.

  14. GWARK S, Kim HJ, Kim J, Chung IY, et al
    ASO Visual Abstract: Survival After Breast-Conserving Surgery Compared with that After Mastectomy in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
    Ann Surg Oncol. 2023 Feb 15. doi: 10.1245/s10434-023-13154.

    BMC Cancer

  15. AL-KEILANI MS, Bdeir R, Elstaty RI, Alqudah MA, et al
    Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
    BMC Cancer. 2023;23:158.
    PubMed         Abstract available

  16. VOLKEL V, Steinger B, Koller M, Klinkhammer-Schalke M, et al
    Colorectal cancer survivors' long-term recollections of their illness and therapy up to seven years after enrolment into a randomised controlled clinical trial.
    BMC Cancer. 2023;23:149.
    PubMed         Abstract available

  17. KARACIN C, Oksuzoglu B, Demirci A, Keskinkilic M, et al
    Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
    BMC Cancer. 2023;23:136.
    PubMed         Abstract available

    Br J Cancer

  18. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Feb 10. doi: 10.1038/s41416-023-02174.
    PubMed         Abstract available

    Breast Cancer (Dove Med Press)

  19. ALSUMAI TS, Alhefdhi A
    Factors Predicting Positive Sentinel Lymph Node Biopsy in Clinically Node-Negative Breast Cancer [Response to Letter].
    Breast Cancer (Dove Med Press). 2023;15:133-134.

  20. LI N, Song C, Huang X, Zhang H, et al
    Optimized Radiomics Nomogram Based on Automated Breast Ultrasound System: A Potential Tool for Preoperative Prediction of Metastatic Lymph Node Burden in Breast Cancer.
    Breast Cancer (Dove Med Press). 2023;15:121-132.
    PubMed         Abstract available

    Breast Cancer Res

  21. LEE ES, Kim Y, Shin HC, Hwang KT, et al
    Diagnostic accuracy of a three-protein signature in women with suspicious breast lesions: a multicenter prospective trial.
    Breast Cancer Res. 2023;25:20.
    PubMed         Abstract available

  22. OUYANG D, Hong T, Fu M, Li Y, et al
    METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
    Breast Cancer Res. 2023;25:19.
    PubMed         Abstract available

  23. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.
    Breast Cancer Res. 2023;25:18.
    PubMed         Abstract available

    Breast Cancer Res Treat

  24. SUND M, Garmo H, Andersson A, Margolin S, et al
    Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk.
    Breast Cancer Res Treat. 2023 Feb 11. doi: 10.1007/s10549-023-06871.
    PubMed         Abstract available

  25. KIM SE, Kim WJ, Choi D, Lee DY, et al
    Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer.
    Breast Cancer Res Treat. 2023 Feb 13. doi: 10.1007/s10549-023-06877.
    PubMed         Abstract available

  26. EOM KY, Berg KA, Joseph NE, Runner K, et al
    Neighborhood and racial influences on triple negative breast cancer: evidence from Northeast Ohio.
    Breast Cancer Res Treat. 2023 Feb 13. doi: 10.1007/s10549-023-06883.
    PubMed         Abstract available

  27. MOTA BS, Reis YN, de Barros N, Cardoso NP, et al
    Effects of preoperative magnetic resonance image on survival rates and surgical planning in breast cancer conservative surgery: randomized controlled trial (BREAST-MRI trial).
    Breast Cancer Res Treat. 2023 Feb 14. doi: 10.1007/s10549-023-06884.
    PubMed         Abstract available

  28. ZHANG H, Zheng J, Fu Y, Ling J, et al
    Overexpression of POU3F2 promotes radioresistance in triple-negative breast cancer via Akt pathway activation.
    Breast Cancer Res Treat. 2023 Feb 17. doi: 10.1007/s10549-023-06876.
    PubMed         Abstract available

  29. GASTOUNIOTI A, Cohen EA, Pantalone L, Ehsan S, et al
    Changes in mammographic density and risk of breast cancer among a diverse cohort of women undergoing mammography screening.
    Breast Cancer Res Treat. 2023 Feb 17. doi: 10.1007/s10549-023-06879.
    PubMed         Abstract available


    Advances in breast cancer presented in San Antonio.
    Cancer. 2023;129:817-818.

  31. LOWRY KP, Ichikawa L, Hubbard RA, Buist DSM, et al
    Variation in second breast cancer risk after primary invasive cancer by time since primary cancer diagnosis and estrogen receptor status.
    Cancer. 2023 Feb 15. doi: 10.1002/cncr.34679.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  32. MUSE ME, Carroll CD, Salas LA, Karagas MR, et al
    Application of novel breast biospecimen cell type adjustment identifies shared DNA methylation alterations in breast tissue and milk with breast cancer risk factors.
    Cancer Epidemiol Biomarkers Prev. 2023 Feb 10:EPI-22-0405.
    PubMed         Abstract available

  33. JOHN EM, Koo J, Ingles SA, Kurian AW, et al
    Changes in breast cancer risk and risk factor profiles among U.S.-born and immigrant Asian American women residing in the San Francisco Bay Area.
    Cancer Epidemiol Biomarkers Prev. 2023 Feb 10:EPI-22-1128.
    PubMed         Abstract available

    Cancer Lett

  34. BERG AL, Showalter MR, Kosaisawe N, Hu M, et al
    Cellular transformation promotes the incorporation of docosahexaenoic acid into the endolysosome-specific lipid bis(monoacylglycerol)phosphate in breast cancer.
    Cancer Lett. 2023;557:216090.
    PubMed         Abstract available

    Cancer Res

  35. MALIK N, Kim YI, Yan H, Tseng YC, et al
    Dysregulation of mitochondrial translation caused by CBFB deficiency cooperates with mutant PIK3CA and is a vulnerability in breast cancer.
    Cancer Res. 2023 Feb 14:CAN-22-2525. doi: 10.1158/0008-5472.CAN-22-2525.
    PubMed         Abstract available

    Clin Breast Cancer

  36. YANG C, Wang M, Huang R, Ou L, et al
    Circ_0108942 Regulates the Progression of Breast Cancer by Regulating the MiR-1178-3p/TMED3 Axis.
    Clin Breast Cancer. 2022 Dec 23:S1526-8209(22)00293.
    PubMed         Abstract available

    Is Taxane Rechallenge Time Dependent in Patients With Advanced Triple-Negative Breast Cancer?
    Clin Breast Cancer. 2023 Jan 25:S1526-8209(23)00020.

    Eur J Cancer

  38. SCHMIDT MK, Kelly JE, Bredart A, Cameron DA, et al
    EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy.
    Eur J Cancer. 2023;181:79-91.
    PubMed         Abstract available

    Eur J Surg Oncol

  39. BARRY PA, Harborough K, Sinnett V, Heeney A, et al
    Clinical utility of axillary nodal markers in breast cancer.
    Eur J Surg Oncol. 2023 Feb 1:S0748-7983(22)01365.
    PubMed         Abstract available


  40. IBRAHIM A, Toss MS, Atallah NM, Al Saleem M, et al
    Combined proliferation and apoptosis index provides better risk stratification in breast cancer.
    Histopathology. 2023 Feb 13. doi: 10.1111/his.14887.
    PubMed         Abstract available

    Int J Cancer

  41. JIA G, Yang Y, Ping J, Xu S, et al
    Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.
    Int J Cancer. 2023 Feb 13. doi: 10.1002/ijc.34472.
    PubMed         Abstract available

    Int J Oncol

  42. OKUI T, Hiasa M, Hasegawa K, Nakamura T, et al
    Lactate secreted via MCT4 from bone‑colonizing breast cancer excites sensory neurons via GPR81.
    Int J Oncol. 2023;62:39.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  43. LIVERINGHOUSE CL, Mills MN, Ahmed KA, Washington IR, et al
    Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Feb 14:S0360-3016(22)03689.
    PubMed         Abstract available

    J Clin Invest

  44. NANDI I, Smith HW, Sanguin-Gendreau V, Ji L, et al
    Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
    J Clin Invest. 2023 Feb 16:e162324. doi: 10.1172/JCI162324.
    PubMed         Abstract available

    J Clin Oncol

  45. NARAYAN P, Dilawari A, Osgood C, Feng Z, et al
    US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.
    J Clin Oncol. 2023 Feb 13:JCO2202447. doi: 10.1200/JCO.22.02447.
    PubMed         Abstract available

  46. YANG S, Tan M, Gao F, Xu X, et al
    Cognitive Problems in Older Breast Cancer Survivors.
    J Clin Oncol. 2023 Feb 13:JCO2202282. doi: 10.1200/JCO.22.02282.

    J Natl Cancer Inst

  47. Correction to: TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
    J Natl Cancer Inst. 2023 Feb 16:djad023. doi: 10.1093.

  48. CHAVEZ-MACGREGOR M, Lei X, Malinowski C, Zhao H, et al
    Medicaid expansion, chemotherapy delays, and racial disparities among women with early-stage breast cancer.
    J Natl Cancer Inst. 2023 Feb 16:djad033. doi: 10.1093.
    PubMed         Abstract available

  49. BIKOMEYE JC, Zhou Y, McGinley EL, Canales B, et al
    Historical Redlining and Breast Cancer Treatment and Survival among older Women in the US.
    J Natl Cancer Inst. 2023 Feb 16:djad034. doi: 10.1093.
    PubMed         Abstract available

    J Surg Oncol

  50. JONCZYK MM, Homsy C, Naber S, Chatterjee A, et al
    Examining a decade of racial disparity in partial mastectomy and oncoplastic surgery.
    J Surg Oncol. 2023;127:541-549.
    PubMed         Abstract available

  51. ILHAN B, Bademler S, Kilic B, Onder S, et al
    The impact of intraoperative cavity shaving on re-excision rates in breast-conserving surgery.
    J Surg Oncol. 2023;127:527-534.
    PubMed         Abstract available

  52. WIENER AA, Schumacher JR, Hanlon B, Anderson B, et al
    Incidence of radiation-associated sarcoma after breast-conserving surgery plus radiation.
    J Surg Oncol. 2023;127:535-540.
    PubMed         Abstract available

    Mod Pathol

  53. ALDREES R, Gao X, Zhang K, Siegal GP, et al
    Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.
    Mod Pathol. 2021;34:291-299.
    PubMed         Abstract available

  54. BAEZ-NAVARRO X, van Bockstal MR, Nawawi D, Broeckx G, et al
    Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
    Mod Pathol. 2023;36:100009.
    PubMed         Abstract available

  55. ROBBINS CJ, Fernandez AI, Han G, Wong S, et al
    Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
    Mod Pathol. 2023;36:100032.
    PubMed         Abstract available

  56. CALHOUN BC, Dabbs DJ
    Lack of Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2023;36:100041.

  57. MUELLER S, Grote I, Bartels S, Kandt L, et al
    p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
    Mod Pathol. 2023;36:100100.
    PubMed         Abstract available

  58. BAEZ-NAVARRO X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM, et al
    HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
    Mod Pathol. 2023;36:100087.
    PubMed         Abstract available

  59. WU S, Yue M, Zhang J, Li X, et al
    The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
    Mod Pathol. 2023;36:100054.
    PubMed         Abstract available

    N Engl J Med

  60. KUNKLER IH, Williams LJ, Jack WJL, Cameron DA, et al
    Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.
    N Engl J Med. 2023;388:585-594.
    PubMed         Abstract available

  61. HO AY, Bellon JR
    Overcoming Resistance - Omission of Radiotherapy for Low-Risk Breast Cancer.
    N Engl J Med. 2023;388:652-653.

    NPJ Breast Cancer

  62. DEBIEN V, De Caluwe A, Wang X, Piccart-Gebhart M, et al
    Immunotherapy in breast cancer: an overview of current strategies and perspectives.
    NPJ Breast Cancer. 2023;9:7.
    PubMed         Abstract available

    Oncol Rep

  63. HAN S, Jin X, Hu T, Chi F, et al
    LAPTM5 regulated by FOXP3 promotes the malignant phenotypes of breast cancer through activating the Wnt/beta‑catenin pathway.
    Oncol Rep. 2023;49:60.
    PubMed         Abstract available

    PLoS One

  64. MAPANGA W, Norris SA, Craig A, Ayeni OA, et al
    Drivers of disparities in stage at diagnosis among women with breast cancer: South African breast cancers and HIV outcomes cohort.
    PLoS One. 2023;18:e0281916.
    PubMed         Abstract available

  65. ALMEIDA SS, Oliveira MA, Medeiros R, Guerra MP, et al
    Emotional, inflammatory, and genetic factors of resilience and vulnerability to depression in patients with premenopausal breast cancer: A longitudinal study protocol.
    PLoS One. 2023;18:e0279344.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  66. BASSEY-ARCHIBONG BI, Rajendra Chokshi C, Aghaei N, Kieliszek AM, et al
    An HLA-G/SPAG9/STAT3 axis promotes brain metastases.
    Proc Natl Acad Sci U S A. 2023;120:e2205247120.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.